天康生物(002100) - 2017 Q1 - 季度财报

Revenue and Profitability - Revenue for Q1 2017 was CNY 1,039,393,448.53, an increase of 8.00% compared to CNY 962,437,096.19 in the same period last year[8] - Net profit attributable to shareholders was CNY 107,299,493.78, reflecting an 11.12% increase from CNY 96,557,711.33 year-on-year[8] - Basic earnings per share increased by 10.00% to CNY 0.11 from CNY 0.10 in the same period last year[8] - The expected net profit attributable to shareholders for the first half of 2017 is projected to range from 172.75 million to 230.34 million yuan, reflecting a change of -10.00% to 20.00% compared to the same period in 2016[24] - The net profit for the first half of 2016 was 191.95 million yuan, indicating a potential decline in profitability due to reduced feed business performance[24] Cash Flow - Net cash flow from operating activities was negative CNY 14,031,872.75, a decline of 107.66% compared to CNY 183,192,982.36 in the previous year[8] - The net cash flow from operating activities decreased by 107.66% compared to the same period last year, primarily due to increased costs and higher cash payments for raw material procurement[19] - The net cash flow from investing activities increased by 59.9% year-on-year, mainly because there were no subsidiary acquisitions in the current period[19] - The net cash flow from financing activities decreased by 1.48% compared to the same period last year, attributed to a slight decline in net loans and repayments[19] Assets and Shareholder Equity - Total assets at the end of the reporting period were CNY 4,453,599,016.06, a decrease of 0.83% from CNY 4,490,817,872.34 at the end of the previous year[8] - Net assets attributable to shareholders increased by 4.08% to CNY 2,736,295,408.41 from CNY 2,628,995,914.63 at the end of the previous year[8] Receivables - Accounts receivable increased by 94.66% compared to the beginning of the year, primarily due to planned government procurement arrears from the pharmaceutical business[17] - Other receivables rose by 122.03% compared to the beginning of the year, mainly due to an increase in travel advance funds[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 65,904[12] Non-Operating Income - The company reported non-operating income of CNY 5,734,263.29, which includes government subsidies and other income[9]